Trial reportDrug design, development and therapy2022
Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Multidimensional clinical evaluation of remimazolam versus propofol and dexmedetomidine: two systematic reviews and meta-analyses based on differentiated endpoints.BMC anesthesiology · 2026Pooled it
- Remimazolam compared to dexmedetomidine on the incidence of hypotension in middle aged and elderly patients undergoing general anesthesia: a systematic review and meta-analysis.BMC anesthesiology · 2025Pooled it
- Remimazolam versus propofol for postoperative delirium prevention in geriatric surgery: A systematic review and meta-analysis of randomized controlled trials.Aging clinical and experimental research · 2025Pooled it
- Cipepofol for adjunctive sedation during neuraxial anesthesia: a study protocol for a randomized controlled trial.Trials · 2026Trial
- Trial
- Efficacy and safety of remimazolam combined with remifentanil for sedation during awake fiberoptic intubation: a randomized controlled trial.Annals of medicine · 2025Trial
- Comparison of remimazolam and dexmedetomidine for conscious sedation in elderly patients undergoing dental implant surgery: a prospective randomized controlled trial.BMC geriatrics · 2025Trial
- Remimazolam vs. dexmedetomidine for postoperative sedation in oral tumor patients undergoing free flap reconstruction: a randomized controlled pilot trial.BMC anesthesiology · 2025Trial
- Remimazolam for the prevention of emergence agitation in adults following nasal surgery under general anesthesia: a prospective randomized clinical controlled trial.BMC anesthesiology · 2025Trial
- Determination of the 90% Effective Dose of Remimazolam Continuous Infusion for Preventing Emergence Delirium in Pediatric Patients Undergoing Adenoidectomy or Adenotonsillectomy with Sevoflurane: A Biased Coin Up-and-Down Sequential Trial Design.Drug design, development and therapy · 2025Trial
- Safety and effcacy of remimazolam tosilate for sedation during combined spinal-epidural anesthesia for orthopedic procedures: a randomized controlled trial.BMC anesthesiology · 2024Trial
- Comparison of the Safety and Efficacy of Remimazolam Besylate versus Dexmedetomidine for Patients Undergoing Fiberoptic Bronchoscopy: A Prospective, Randomized Controlled Trial.Drug design, development and therapy · 2024Trial
- Effects of Remimazolam and Propofol on Emergence Agitation in Elderly Patients Undergoing Hip Replacement: A Clinical, Randomized, Controlled Study.Drug design, development and therapy · 2023Trial
- The Impact of General Anesthetics on Postoperative Delirium: A Narrative Review Based on Clinical Randomized Controlled Trials from the Last Five Years.Geriatrics (Basel, Switzerland) · 2026Review
- Remimazolam is associated with superior cerebral and pulmonary protection over propofol in elderly thoracic surgery: a real-world study validated by propensity score matching.Frontiers in medicine · 2026Article
- What Every Intensivist Should Know About Remimazolam.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- Rapid Alertness: A Propensity-score Matched, Prospective Observational Study of Remimazolam vs. Propofol Infusion for Sedation in Spinal Anesthesia Non-healthy Patients.Oman medical journal · 2025Article
- Advancing Delirium Treatment Trials in Older Adults: Recommendations for Future Trials From the Network for Investigation of Delirium: Unifying Scientists (NIDUS).Critical care medicine · 2025Article
- Perioperative dexmedetomidine effects on delirium in elderly patients after noncardiac surgery: A retrospective propensity score analysis.Frontiers in pharmacology · 2025Article
- The sedation efficacy of different doses of remimazolam in elderly patients with regional nerve block anaesthesia.European journal of medical research · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of the present study was to investigate the efficacy and safety of remimazolam besylate compared with dexmedetomidine for the relief of agitated delirium in non-intubated older patients after orthopedic surgery. Patients and methods: Seventy-five patients were randomly divided into two groups. Patients assigned to the remimazolam group received a loading dose of 0.075 mg/kg remimazolam besylate over 1 minute, followed by a continuous infusion of 0.1 to 0.3 mg/kg/h. Subjects randomized to the dexmedetomidine group received a loading infusion of 0.5 μg/kg dexmedetomidine over 10 minutes, followed by a maintenance dose of 0.2 to 0.7 μg/kg/h. Meanwhile, RASS score-guided dose titration was followed. To assess the efficacy of the study drugs in terms of time to resolution of agitation, time to first achievement of target sedation, percentage of time within the target sedation range, and time to delirium resolution. Safety of the sedatives was evaluated by adverse events during hospitalization. Results: Time to resolution of agitation did not differ between the two groups. The time to first achievement of target sedation was 19.0 (9.5 to 31.0) minutes for remimazolam besylate vs 43.5 (15.0 to 142.5) minutes for dexmedetomidine ( Conclusion: Compared with dexmedetomidine, remimazolam besylate was equally effective in relieving agitation, and resulted in earlier achievement of sedation goal and more controllable sedation. Remimazolam may be an ideal agent for obtaining rapid tranquillisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.